# US 10,245,226 B2 · Method for preventing nasolacrimal duct obstruction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,226 B2
- Document ID: US10245226B2
- Status: Granted
- Kind: B2
- Application number: 15/925,260
- Filed: 2018-03-19
- Published: 2018-07-26
- Granted: 2019-04-02
- Earliest claimed: 2005-04-25
- Assignees: Kem Patent Holdings, LLC
- Applicants: Kem Patent Holdings, LLC
- Inventors: Kenneth Eli Morgenstern
- Web page: https://patentgrep.com/patent/US10245226B2

## CPC

- A61K 9/0046: {Ear}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 33/18: Iodine; Compounds thereof
- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 33/40: Peroxides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/00: Preparations containing radioactive substances for use in therapy or testing in vivo
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0012: {Galenical forms characterised by the site of application}
- A61K 9/0043: {Nose}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer. The method includes administering an effective amount of perchlorate anion to the eyes of the patient.

## Claims

### Claim 1

A method for reducing formation of fibrosis in at least one nasolacrimal duct of a patient that may occur upon the patient receiving radioactive iodine, the method comprising administering to the patient a therapeutically effective amount of perchlorate anion, wherein the administering is topically administering perchlorate anion to at least one eye of the patient, or instilling the perchlorate anion directly into the at least one nasolacrimal duct or at least one lacrimal sac of the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the radioactive iodine is high dose I131.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient receiving radioactive iodine is receiving the radioactive iodine for treatment of cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer is head and neck cancer, thyroid cancer, or breast cancer.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the administering occurs for a period of from 3 to 5 days prior to initiation of the radioactive iodine treatment.

### Claim 6 (depends on 5)

The method according to claim 5, wherein administering continues for as long as the patient receives the radioactive iodine.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the source of the perchlorate anion is a compound selected from the group comprising potassium perchlorate, sodium perchlorate, ammonium perchlorate and perchloric acid.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the administering comprises the step of topically administering perchlorate anion to the at least one eye of the patient as a topical liquid, gel, cream or ointment.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the step of topically administering to one eye of the at least one eye comprises administering a drop having a volume of 50 μl to 75 μl to the one eye.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the step of topically administering comprising topically administering at intervals of treatment time points to produce higher drug concentrations in the at least one nasolacrimal duct for each treatment time point.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the administering comprises the step of instilling.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the patient receiving radioactive iodine is receiving the radioactive iodine to treat a condition selected from the group consisting of Grave's disease, tumor of the pituitary gland, tumor of the testes, tumor of the ovaries, inflammation of the thyroid, and ingestion of excessive amounts of thyroid hormone.

### Claim 13 (depends on 1)

The method of claim 1, wherein the patient receiving radioactive iodine is receiving the radioactive iodine for treatment of hyperthyroidism.

### Claim 14 (depends on 1)

The method of claim 1, wherein the radioactive iodine is I123.